Pembrolizumab (pembro) as first-line therapy for advanced/unresectable or metastatic urothelial cancer: Preliminary results from the phase 2 KEYNOTE-052 study Meeting Abstract
| Authors: | Balar, A.; Bellmunt, J.; O'Donnell, P. H.; Castellano, D.; Grivas, P.; Vuky, J.; Powles, T.; Plimack, E. R.; Hahn, N. M.; de Wit, R.; Pang, L.; Savage, M. J.; Perini, R.; Keefe, S.; Bajorin, D. |
| Abstract Title: | Pembrolizumab (pembro) as first-line therapy for advanced/unresectable or metastatic urothelial cancer: Preliminary results from the phase 2 KEYNOTE-052 study |
| Meeting Title: | 41st European Society for Medical Oncology Congress (ESMO) |
| Journal Title: | Annals of Oncology |
| Volume: | 27 |
| Issue: | Suppl. 6 |
| Meeting Dates: | 2016 Oct 7-11 |
| Meeting Location: | Copenhagen, Denmark |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2016-10-01 |
| Start Page: | vi567 |
| Language: | English |
| ACCESSION: | WOS:000393913000714 |
| DOI: | 10.1093/annonc/mdw435.25 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: LBA32_PR -- Source: Wos |
